Efficacy and safety of daclatasvir and asunaprevir in chronic hepatitis C patients with hemodialysis

Efficacy and safety of daclatasvir and asunaprevir in chronic hepatitis C patients with hemodialysis - Efficacy of daclatasvir and asunaprevir in chronic hepatitis C patients with hemodialysis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016181

Enrollment

Registered

2015-01-14

Start date

2015-01-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis C with hemodialysis

Interventions

Asunaprevir 200mg twice daily and daclatasvir 60mg once daily for 24 weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Chronic hepatitis or cirrhosis patients with HCV genotype 1 (2) Patients with hemodialysis (3) Patients with 20 years of age and older

Exclusion criteria

Exclusion criteria: (1) Decompensated cirrhosis, Liver failure (2)patients with hepatic cell carcinoma (3) Co-infection with hepatitis B virus Co-infection with anti- humanimmunodeficiency virus

Design outcomes

Primary

Measure	Time frame
Sustained virologic response rate at 24 weeks post-treatment	—

Secondary

Measure	Time frame
Safety The factor associated with sustained virologic response Emergence of drug-resistant virus Cumulative incidence of hepatocellular carcinoma	—

Countries

Japan

Contacts

Public Contactuojima haruki

shonan kamakura general hospital department of gastroenterology

kiruha555@yahoo.co.jp0467-46-1717

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026